Membranous NECTIN-4 expression in metastasis versus matched primary tumor more accurately predicts enfortumab vedotin response

被引：0
|
作者：
Buettner, T. [1 ]
Zschaebitz, S. [2 ]
Bolenz, C. [3 ]
Zengerling, F. [3 ]
Heers, H. [4 ]
Nagy, D. [5 ]
Toma, M. [5 ]
Kristiansen, G. [5 ]
Ellinger, J. [1 ]
Ritter, M. [1 ]
Hartmann, A. [6 ]
Hoelzel, M. [7 ]
Eckstein, M. [6 ]
Kluemper, N. [1 ]
机构：
[1] Univ Hosp Bonn, Dept Urol & Paediat Urol, Bonn, Germany
[2] Univ Hosp Heidelberg, Dept Med Oncol, Heidelberg, Germany
[3] Univ Hosp Ulm, Dept Urol & Paediat Urol, Ulm, Germany
[4] Univ Hosp Marburg, Dept Urol, Marburg, Germany
[5] Univ Hosp Bonn, Inst Pathol, Bonn, Germany
[6] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
[7] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0750
引用
收藏
页码：S1727 / S1727
页数：1
相关论文
共 11 条
  • [1] Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer
    Weiten, Richard
    Bernhardt, Marit
    Niemann, Max
    Kristiansen, Glen
    Gruenwald, Viktor
    Ritter, Manuel
    Hoelzel, Michael
    Eckstein, Markus
    Alajati, Abdullah
    Kluemper, Niklas
    Krausewitz, Philipp
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (14)
  • [2] Loss of membranous NECTIN-4 occurs frequently during metastatic spread of urothelial carcinoma and predicts resistance to enfortumab vedotin
    Kluemper, N.
    Ralser, D. J.
    Ellinger, J.
    Roghmann, F.
    Breyer, J.
    Bolenz, C.
    Zengerling, F.
    Erben, P.
    Schwamborn, K.
    Horn, T.
    Kristiansen, G.
    Gruenwald, V.
    Darr, C.
    Rausch, S.
    Schlack, K.
    Zschaebitz, S.
    Wullich, B.
    Ritter, M.
    Hartmann, A.
    Gschwend, J. E.
    Weichert, W.
    Erlmeier, F.
    Hoelzel, M.
    Eckstein, M.
    EUROPEAN UROLOGY, 2023, 83 : S772 - S773
  • [3] Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
    Kluemper, Niklas
    Ralser, Damian J.
    Ellinger, Joerg
    Roghmann, Florian
    Albrecht, Julia
    Below, Eduard
    Alajati, Abdullah
    Sikic, Danijel
    Breyer, Johannes
    Bolenz, Christian
    Zengerling, Friedemann
    Erben, Philipp
    Schwamborn, Kristina
    Wirtz, Ralph M.
    Horn, Thomas
    Nagy, Dora
    Toma, Marieta
    Kristiansen, Glen
    Buettner, Thomas
    Hahn, Oliver
    Gruenwald, Viktor
    Darr, Christopher
    Erne, Eva
    Rausch, Steffen
    Bedke, Jens
    Schlack, Katrin
    Abbas, Mahmoud
    Zschaebitz, Stefanie
    Schwab, Constantin
    Mustea, Alexander
    Adam, Patrick
    Manseck, Andreas
    Wullich, Bernd
    Ritter, Manuel
    Hartmann, Arndt
    Gschwend, Jurgen
    Weichert, Wilko
    Erlmeier, Franziska
    Hoelzel, Michael
    Eckstein, Markus
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1496 - 1505
  • [4] Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin
    Cho, Woo Cheal
    Saade, Rayan
    Nagarajan, Priyadharsini
    Aung, Phyu P.
    Milton, Denai R.
    Marques-Piubelli, Mario L.
    Hudgens, Courtney
    Ledesma, Debora
    Nelson, Kelly
    Ivan, Doina
    Zhang, Miao
    Torres-Cabala, Carlos A.
    Campbell, Matthew
    Alhalabi, Omar
    Prieto, Victor G.
    Wistuba, Ignacio I.
    Esmaeli, Bita
    Curry, Jonathan L.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2024, 51 (05) : 360 - 367
  • [5] High Expression of Nectin-4 in a Subset of Adnexal Carcinomas: A Potential Target for Enfortumab Vedotin Therapy
    Saade, Rayan
    Cho, Woo Cheal
    Nagarajan, Priya
    Aung, Phyu
    Marques-Piubelli, Mario
    Hudgens, Courtney
    Ledesma, Debora
    Nelson, Kelly
    Heberton, Meghan
    Ivan, Doina
    Zhang, Miao
    Torres-Cabala, Carlos
    Campbell, Matthew
    Prieto, Victor
    Wistuba, Ignacio
    Esmaeli, Bita
    Curry, Jonathan
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 354 - 356
  • [6] High Expression of Nectin-4 in a Subset of Adnexal Carcinomas: A Potential Target for Enfortumab Vedotin Therapy
    Saade, Rayan
    Cho, Woo Cheal
    Nagarajan, Priya
    Aung, Phyu
    Marques-Piubelli, Mario
    Hudgens, Courtney
    Ledesma, Debora
    Nelson, Kelly
    Heberton, Meghan
    Ivan, Doina
    Zhang, Miao
    Torres-Cabala, Carlos
    Campbell, Matthew
    Prieto, Victor
    Wistuba, Ignacio
    Esmaeli, Bita
    Curry, Jonathan
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 354 - 356
  • [7] Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.
    Chu, Carissa
    Sjostrom, Martin
    Egusa, Emily A.
    Gibb, Ewan
    Badura, Michelle L.
    Koshkin, Vadim S.
    Stohr, Bradley A.
    Meng, Maxwell
    Pruthi, Raj
    Friedlander, Terence W.
    Lotan, Yair
    Black, Peter C.
    Porten, Sima P.
    Feng, Felix Y.
    Chou, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
    Kluemper, Niklas
    Tran, Ngoc Khanh
    Zschaebitz, Stefanie
    Hahn, Oliver
    Buettner, Thomas
    Roghmann, Florian
    Bolenz, Christian
    Zengerling, Friedemann
    Schwab, Constantin
    Nagy, Dora
    Toma, Marieta
    Kristiansen, Glen
    Heers, Hendrik
    Ivanyi, Philipp
    Niegisch, Guenter
    Grunewald, Camilla Marisa
    Darr, Christopher
    Farid, Arian
    Schlack, Katrin
    Abbas, Mahmoud
    Aydogdu, Can
    Casuscelli, Jozefina
    Mokry, Theresa
    Mayr, Michael
    Niedersuess-Beke, Dora
    Rausch, Steffen
    Dietrich, Dimo
    Saal, Jonas
    Ellinger, Joerg
    Ritter, Manuel
    Alajati, Abdullah
    Kuppe, Christoph
    Meeks, Joshua
    Badillo, Francisco E. Vera
    Nakauma-Gonzalez, J. Alberto
    Boormans, Joost
    Junker, Kerstin
    Hartmann, Arndt
    Gruenwald, Viktor
    Hoelzel, Michael
    Eckstein, Markus
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (20) : 2446 - 2455
  • [9] Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models
    Moreno, Crystal
    Flores, Johnnie
    Simonson, Alyssa
    DeBoer, Maci
    Banos, Natalia
    Diaz, Armando, III
    Lynch, Morgan
    Lund, Jim
    Leykum, Leonora
    Rouzbahan, Tahmi
    Pedregal, Manuel
    Papadopoulos, Kyriakos P.
    Lang, Amy
    Rosenthal, Arthur
    Rasco, Drew
    Rodriguez, Gladys
    Rodriguez, Luis
    Lakhani, Nehal
    Beeram, Muralidhar
    Patnaik, Amita
    De Miguel, Maria
    Drengler, Ronald
    Abbate, Steven
    Uribe, Bernard Doger de Speville
    Wick, Michael
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer
    Carosino, Christopher
    Olson, Devra
    Snead, Katie
    Lee, Anthony
    Farr, Lauren
    Garg, Amit
    O'Day, Christine
    Trueblood, Esther
    Wright, Jennifer
    Bieda, Mark
    Caldwell, Charles
    Hensley, Kelly
    Allred, Sean
    Liu, Bernard
    Shimazaki, Masashi
    Sandall, Sharsti
    CANCER RESEARCH, 2022, 82 (12)
12